Proteína contendo domínios Ras e EF-hand, também conhecida como proteína relacionada a Ras Rab-45, é uma proteína que em humanos é codificada pelo gene RASEF.
Introdução
O que você precisa saber de cara
Visão geral
A Hemopatia mieloide é uma doença hematológica rara que afeta a medula óssea e o sangue. Ela se caracteriza por uma neoplasia hematológica, ou seja, uma proliferação anormal de células do sangue, e está associada a alterações na morfologia e função das células sanguíneas. A condição pode se manifestar com uma variedade de sintomas que impactam a qualidade de vida do paciente.[1][2]
Sinais e sintomas
Os sinais e sintomas da Hemopatia mieloide são variados e podem incluir: fadiga fácil, palidez anêmica, palpitações, edema pedal (inchaço nos pés), dor lombar, dor no flanco, hepatoesplenomegalia (aumento do fígado e baço), caquexia (perda de peso e massa muscular), sintomas constitucionais (como febre e suores noturnos) e hemorragia retiniana (sangramento na retina). Alterações laboratoriais comuns são anemia macrocítica, anisocitose (variação no tamanho das hemácias), aumento da contagem de micromegacariócitos, níveis anormais de albumina e proteínas circulantes, além de anormalidades na morfologia dos neutrófilos e das células estromais da medula óssea. A doença também pode cursar com mielodisplasia de linhagem múltipla, leucemia mielomonocítica aguda, função ventricular cardíaca anormal, positividade de autoanticorpos e presença de hemangiomas.[1][2]
Causas genéticas
A Hemopatia mieloide está associada a alterações em diversos genes que desempenham papéis importantes na regulação do crescimento e diferenciação celular. Os genes identificados incluem: MLLT10 (proteína AF-10), DEK (proteína DEK), TBL1XR1 (proteína F-box-like/WD repeat-containing TBL1XR1), NABP1 (subunidade B2 do complexo SOSS), PML (proteína PML), MRTFA (fator de transcrição relacionado à miocardina A), STAT5B (transdutor de sinal e ativador da transcrição 5B), RUNX1T1 (proteína CBFA2T1), CBFB (subunidade beta do fator de ligação ao core), MYH11 (miosina-11), BCOR (co-repressor BCL-6) e TGM6 (proteína-glutamina gama-glutamiltransferase 6). Essas alterações genéticas podem contribuir para o desenvolvimento da doença.[1][3]
Diagnóstico
O diagnóstico da Hemopatia mieloide é baseado na avaliação clínica, exames laboratoriais e testes genéticos. Estão disponíveis 336 testes genéticos para a doença, e 263 variantes foram registradas no ClinVar, um banco de dados público que relaciona variantes genéticas a fenótipos clínicos. A análise genética pode auxiliar na confirmação diagnóstica e na identificação de alterações específicas associadas à condição.[1][3]
Tratamento e manejo
As informações sobre tratamento e manejo da Hemopatia mieloide são limitadas. Não há medicamentos específicos aprovados ou procedimentos padronizados no Sistema Único de Saúde (SUS) para esta condição. O manejo é geralmente individualizado, baseado nos sintomas e nas necessidades de cada paciente, e pode incluir suporte clínico para complicações como anemia e infecções. É fundamental que o paciente seja acompanhado por uma equipe médica especializada em doenças hematológicas raras.[1]
Prognóstico e qualidade de vida
Não há dados específicos sobre o prognóstico da Hemopatia mieloide nos fatos fornecidos. A qualidade de vida pode ser impactada pelos sintomas e complicações da doença, como fadiga, anemia e risco de transformação para leucemia aguda. O acompanhamento regular com uma equipe multidisciplinar é essencial para monitorar a evolução da condição e oferecer suporte adequado ao paciente e sua família.[1][2]
Conteúdo informativo gerado e mantido automaticamente a partir de fontes oficiais (Orphanet, HPO, OMIM, SUS). Não substitui avaliação médica.
A **hemopatia mieloide** é uma categoria que engloba diferentes condições com alterações nas células de linhagem mieloide do sangue e da medula óssea. As famílias costumam notar sinais de cansaço fácil, palidez, perda de peso e aumento de volume no abdômen decorrente do aumento do fígado ou baço. No entanto, esta condição não possui um protocolo clínico oficial (PCDT) próprio para doenças raras no Ministério da Saúde, sendo o acompanhamento conduzido pela rede do SUS.
Proteína contendo domínios Ras e EF-hand, também conhecida como proteína relacionada a Ras Rab-45, é uma proteína que em humanos é codificada pelo gene RASEF.
Tem tratamento?
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Partes do corpo afetadas
+ 95 sintomas em outras categorias
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 200 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Genes associados
56 genes identificados com associação a esta condição.
Pierpont syndrome
An autosomal dominant syndrome characterized by multiple congenital anomalies, global developmental delay, learning disability, palmar and plantar fat pads, and distinctive facial characteristics, especially when smiling.
Growth hormone insensitivity syndrome with immune dysregulation 1, autosomal recessive
An autosomal recessive form of growth hormone insensitivity syndrome, a congenital disease characterized by short stature, growth hormone deficiency in the presence of normal to elevated circulating concentrations of growth hormone, resistance to exogeneous growth hormone therapy, and recurrent infections. Most, but not all, patients have features of immune dysregulation.
Microphthalmia, syndromic, 2
A very rare multiple congenital anomaly syndrome characterized by eye anomalies (congenital cataract, microphthalmia, or secondary glaucoma), facial abnormalities (long narrow face, high nasal bridge, pointed nose with cartilages separated at the tip, cleft palate, or submucous cleft palate), cardiac anomalies (atrial septal defect, ventricular septal defect, or floppy mitral valve) and dental abnormalities (canine radiculomegaly, delayed dentition, oligodontia, persistent primary teeth, or variable root length). Microphthalmia is a disorder of eye formation, ranging from small size of a single eye to complete bilateral absence of ocular tissues (anophthalmia). In many cases, microphthalmia/anophthalmia occurs in association with syndromes that include non-ocular abnormalities.
Spinocerebellar ataxia 35
A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA35 patients commonly show upper limb involvement and torticollis. There is no cognitive impairment.
Wiedemann-Steiner syndrome
A syndrome characterized by hairy elbows (hypertrichosis cubiti), intellectual disability, a distinctive facial appearance, and short stature. Facial characteristics include long eyelashes, thick or arched eyebrows with a lateral flare, and downslanting and vertically narrow palpebral fissures.
Skeletal defects, genital hypoplasia, and impaired intellectual development
A disorder characterized by intellectual disability, craniofacial dysmorphism, microcephaly and short stature. Additional features include absence of the thumbs, hypoplasia of the radii and ulnae, additional vertebrae and ribs, retarded bone age and genital hypoplasia.
Hyper-IgE syndrome 1, autosomal dominant, with recurrent infections
A rare disorder of immunity and connective tissue characterized by immunodeficiency, chronic eosinophilia, distinctive coarse facial appearance, abnormal dentition, hyperextensibility of the joints, and bone fractures.
Bone marrow failure syndrome 2
An autosomal recessive disorder characterized by trilineage bone marrow failure, bone marrow hypocellularity, learning difficulties, and microcephaly. Insufficient hematopoiesis results in peripheral blood cytopenias, affecting myeloid, erythroid and megakaryocyte lines. Cutaneous features and increased chromosome breakage are not features.
Carney complex 1
CNC is a multiple neoplasia syndrome characterized by spotty skin pigmentation, cardiac and other myxomas, endocrine tumors, and psammomatous melanotic schwannomas.
Leukemia, chronic myeloid
A clonal myeloproliferative disorder of a pluripotent stem cell with a specific cytogenetic abnormality, the Philadelphia chromosome (Ph), involving myeloid, erythroid, megakaryocytic, B-lymphoid, and sometimes T-lymphoid cells, but not marrow fibroblasts.
Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia
A syndrome characterized by a phenotype reminiscent of Noonan syndrome. Clinical features are highly variable, including facial dysmorphism, short neck, developmental delay, hyperextensible joints and thorax abnormalities with widely spaced nipples. The facial features consist of triangular face with hypertelorism, large low-set ears, ptosis, and flat nasal bridge. Some patients manifest cardiac defects. Some have an increased risk for certain malignancies, particularly juvenile myelomonocytic leukemia.
Tatton-Brown-Rahman syndrome
An overgrowth syndrome characterized by a distinctive facial appearance, tall stature and intellectual disability. Facial gestalt is characterized by a round face, heavy horizontal eyebrows and narrow palpebral fissures. Less common features include atrial septal defects, seizures, umbilical hernia, and scoliosis.
Intellectual developmental disorder, autosomal dominant 42
A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD42 patients manifest global developmental delay commonly accompanied by hypotonia, seizures of various types, ophthalmological manifestations, and poor growth.
Tumoral calcinosis, normophosphatemic, familial
An uncommon, life-threatening disorder characterized by progressive deposition of calcified masses in cutaneous and subcutaneous tissues. Serum phosphate levels are normal. Clinical features include painful calcified ulcerative lesions and massive calcium deposition in the mid- and lower dermis, severe skin and bone infections, erythematous papular skin eruption in infancy, conjunctivitis, and gingivitis. NFTC shows a striking resemblance to acquired dystrophic calcinosis, in which tissue calcification occurs as a consequence of tissue injury/inflammation.
Ataxia-pancytopenia syndrome
An autosomal dominant disorder characterized by cerebellar ataxia, variable hematologic cytopenias, and predisposition to bone marrow failure and myeloid leukemia.
Neurofibromatosis 1
A disease characterized by patches of skin pigmentation (cafe-au-lait spots), Lisch nodules of the iris, tumors in the peripheral nervous system and fibromatous skin tumors. Individuals with the disorder have increased susceptibility to the development of benign and malignant tumors.
Piebald trait
Autosomal dominant genetic developmental abnormality of pigmentation characterized by congenital patches of white skin and hair that lack melanocytes.
Leukemia, chronic myeloid
A clonal myeloproliferative disorder of a pluripotent stem cell with a specific cytogenetic abnormality, the Philadelphia chromosome (Ph), involving myeloid, erythroid, megakaryocytic, B-lymphoid, and sometimes T-lymphoid cells, but not marrow fibroblasts.
Amegakaryocytic thrombocytopenia, congenital, 1
An autosomal recessive form of congenital amegakaryocytic thrombocytopenia, a hematologic disorder characterized by severe reduction of megakaryocytes and platelets at birth, and evolving into generalized bone marrow aplasia during childhood.
Leukemia, acute myelogenous
A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.
X-linked dyserythropoietic anemia and thrombocytopenia
Disorder characterized by erythrocytes with abnormal size and shape, and paucity of platelets in peripheral blood. The bone marrow contains abundant and abnormally small megakaryocytes.
LEOPARD syndrome 1
A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness.
Leukemia, acute myelogenous
A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.
Bohring-Opitz syndrome
A syndrome characterized by severe intrauterine growth retardation, poor feeding, profound intellectual disability, trigonocephaly, prominent metopic suture, exophthalmos, nevus flammeus of the face, upslanting palpebral fissures, hirsutism, and flexion of the elbows and wrists with deviation of the wrists and metacarpophalangeal joints.
Celiac disease 13
A multifactorial, chronic disorder of the small intestine caused by intolerance to gluten. It is characterized by immune-mediated enteropathy associated with failed intestinal absorption, and malnutrition. In predisposed individuals, the ingestion of gluten-containing food such as wheat and rye induces a flat jejunal mucosa with infiltration of lymphocytes.
Leukemia, juvenile myelomonocytic
An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages.
Leukemia, acute myelogenous
A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.
Medicamentos e terapias
Mecanismo: CRL4(CRBN) E3 ubiquitin ligase modulator
Mecanismo: DNA (cytosine-5)-methyltransferase 3A inhibitor
Mecanismo: DNA (cytosine-5)-methyltransferase 3A inhibitor
Mecanismo: Transforming growth factor beta inhibitor
Mecanismo: Cytidine deaminase inhibitor
Mecanismo: DNA topoisomerase II alpha inhibitor
Mecanismo: Myeloid cell surface antigen CD33 binding agent
Mecanismo: Granulocyte-macrophage colony-stimulating factor receptor agonist
Mecanismo: Protein kinase C (PKC) inhibitor
Variantes genéticas (ClinVar)
263 variantes patogênicas registradas no ClinVar.
Vias biológicas (Reactome)
429 vias biológicas associadas aos genes desta condição.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Hemopatia mieloide
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Pesquisa e ensaios clínicos
Nenhum ensaio clínico registrado para esta condição.
Publicações mais relevantes
[Recommendations from the GBMHM and the Fi-LMC for the diagnosis and management of chronic myeloid leukemia].
Para pacientes e médicos, biólogos moleculares são cruciais na Leucemia Mieloide Crônica (LMC). Eles identificam a fusão BCR::ABL1 para o diagnóstico e monitoram a doença residual (DRM) durante o tratamento, avaliando a resposta e identificando resistência. Essas análises guiam a adaptação do tratamento, especialmente em casos de resistência (identificando mutações), garantindo decisões terapêuticas otimizadas e o melhor cuidado ao paciente.
🇧🇷 traduzidoMidostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia.
Este estudo sobre leucemia mieloide aguda (LMA) com mutação FLT3-ITD e o uso de midostaurina (MIDO) revelou que, embora a MIDO reduza a persistência da mutação na recidiva, a presença de múltiplos clones FLT3-ITD no diagnóstico está associada a maior persistência da doença mesmo com o tratamento. Além disso, microclones podem evoluir para se tornarem dominantes na recidiva. Para pacientes e médicos, isso indica que a avaliação da diversidade clonal no diagnóstico é crucial para entender o risco de recaída e planejar estratégias terapêuticas mais eficazes.
🇧🇷 traduzidoAnalysis of peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomes.
Conditional survival of children, adolescents and young adults (0-24 years) diagnosed with leukaemia during 2000-2014 world-wide: (CONCORD-3).
Este estudo global sobre a leucemia em crianças, adolescentes e jovens adultos (0-24 anos) destaca que a sobrevida condicional – a probabilidade de viver mais tempo após ter sobrevivido aos primeiros anos – é um indicador crucial. Para pacientes com leucemia mieloide aguda, a sobrevida é consistentemente 5-10% menor do que para a leucemia linfoide, e embora crianças em países de alta renda apresentem taxas de sobrevida acima de 90%, pacientes mais velhos e de países de baixa renda enfrentam prognósticos menos favoráveis. Contudo, superar os primeiros anos após o diagnóstico melhora significativamente as chances de sobrevida a longo prazo, enfatizando a importância do acesso precoce e contínuo a tratamentos ótimos para médicos e pacientes.
🇧🇷 traduzidoSurvival of European children, adolescents and young adults diagnosed with haematological malignancies in the period 2000-2013: Results from EUROCARE-6, a population-based study.
Este estudo europeu sobre hemopatias mieloides revela que adolescentes e jovens adultos (AYAs) geralmente apresentam uma sobrevida pior para leucemia mieloide aguda (LMA) em comparação com crianças, embora tenham melhor prognóstico para leucemia mieloide crônica (LMC). Apesar do aumento da sobrevida para AYAs com LMA e LMC entre 2000 e 2013, o estudo sublinha que, para a maioria das hemopatias, o prognóstico dos AYAs ainda é inferior ao das crianças. Para médicos e pacientes, isso enfatiza a necessidade contínua de mais pesquisas e terapias especializadas para melhorar a sobrevida deste grupo etário.
🇧🇷 traduzidoPublicações recentes
A Rare Hybrid Presentation: Coexistence of Necrotizing and Histiocytoid Variants of Sweet Syndrome (SS) in a Patient With Acute Myeloid Leukemia (AML).
Multifocal Posterior Pigment Epitheliopathy Complicated by Circumferential Choroidal Detachment Treated With Fluorescein Angiography-Guided Focal Laser Photocoagulation: A Case Report.
Case Report: Chronic myeloid leukemia in a 13-year-old-a rare pediatric case of extreme hyperleukocytosis in chronic phase.
Acid ceramidase inhibition enhances BCL-2 targeting in venetoclax-resistant acute myeloid leukemia.
The interplay between probiotics and mast cells in gut inflammation: a mini-review.
📚 EuropePMCmostrando 77
[Recommendations from the GBMHM and the Fi-LMC for the diagnosis and management of chronic myeloid leukemia].
Bulletin du cancerConditional survival of children, adolescents and young adults (0-24 years) diagnosed with leukaemia during 2000-2014 world-wide: (CONCORD-3).
European journal of cancer (Oxford, England : 1990)Survival of European children, adolescents and young adults diagnosed with haematological malignancies in the period 2000-2013: Results from EUROCARE-6, a population-based study.
European journal of cancer (Oxford, England : 1990)Short-term neurological tolerance of chimeric antigen receptor-T cell therapy for refractory B-cell malignancy in patients with pre-existing cognitive impairment: A retrospective cohort study.
Journal of geriatric oncologyAnalysis of peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomes.
Blood advancesLong-term survival for myeloid neoplasms and national health expenditure: A EUROCARE-6 retrospective, population-based study.
European journal of cancer (Oxford, England : 1990)HLA evolutionary divergence score after donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation.
HemaSphere[VEXAS-like auto inflammatory syndrome: 2 cases].
La Revue de medecine interneMacrophages as Potential Therapeutic Targets in Acute Myeloid Leukemia.
BiomedicinesMidostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia.
Blood advances[Place of hematopoietic stem cell transplantation for very high risk acute myeloblastic leukemia and myelodysplastic syndromes (SFGM-TC)].
Bulletin du cancerSodium diethyldithiocarbamate trihydrate: an effective and selective compound for hematological malignancies.
Naunyn-Schmiedeberg's archives of pharmacologyFrom Skin to Blood: Ulcerative Pyoderma Gangrenosum Unveiling Acute Myeloid Leukemia.
CureusOptimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia.
Blood advancesThe t(X;20)(q13;q13) translocation is a good prognostic factor in myeloid neoplasms: A report of 25 cases from the Groupe Francophone de Cytogénétique Hématologique.
American journal of hematologyLeukemia cutis revealing relapse of a chronic myeloid leukemia: A case report.
Clinical case reportsIntegrative single-cell expression and functional studies unravels a sensitization to cytarabine-based chemotherapy through HIF pathway inhibition in AML leukemia stem cells.
HemaSphereSingle-cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy.
Cancer research communicationsCytogenetics in the management of acute myeloid leukemia and histiocytic/dendritic cell neoplasms: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH).
Current research in translational medicineA human genome editing-based MLL::AF4 ALL model recapitulates key cellular and molecular leukemogenic features.
Blood[Dysimmune manifestations associated with myelodysplastic neoplasms and chronic myelomonocytic leukaemias].
Bulletin du cancerMeasurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical OncologyA miRNA signature related to stemness identifies high-risk patients in paediatric acute myeloid leukaemia.
British journal of haematologyHereditary predisposition to malignant myeloid hemopathies: Caution in use of saliva and guideline based on our experience.
Frontiers in oncologyFactors influencing access to specialised haematology units during acute myeloblastic leukaemia patient care: A population-based study in France.
Cancer medicineTIM3, a human acute myeloid leukemia stem cell marker, does not enrich for leukemia-initiating stem cells in B-cell acute lymphoblastic leukemia.
HaematologicaThe presence of a chromosomal abnormality in cytopenia without dysplasia identifies a category of high-risk clonal cytopenia of unknown significance.
Genes, chromosomes & cancerHypodiploidy has unfavorable impact on survival in pediatric acute myeloid leukemia: an I-BFM Study Group collaboration.
Blood advancesCritical Role of Aquaporins in Cancer: Focus on Hematological Malignancies.
CancersGenetics and Epigenetics in Neoplasms with Plasmacytoid Dendritic Cells.
CancersReduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases.
Clinical and experimental medicineVenous thromboembolism during systemic inflammatory and autoimmune diseases associated with myelodysplastic syndromes, chronic myelomonocytic leukaemia and myelodysplastic/myeloproliferative neoplasms: a French multicentre retrospective case-control study.
Clinical and experimental rheumatology[Prevalence of Adverse Effects of Tyrosine Kinase Inhibitors Used in Management of Chronic Myeloid Leukemia at Sidi Bel-Abbès University Hospital Center].
Annales pharmaceutiques francaisesPhotodistributed pustular acute febrile neutrophilic dermatosis revealing an acute myeloid leukemia.
Clinical case reportsHidden in the Eyes-Recurrence of Systemic Hemopathies Reportedly "In Remission": Six Cases and Review of Literature.
Medicina (Kaunas, Lithuania)Nodal cytotoxic peripheral T-cell lymphoma occurs frequently in the clinical setting of immunodysregulation and is associated with recurrent epigenetic alterations.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, IncDonor-Derived Leukemia in a Recipient of Double-Unit Cord Blood Transplantation for Acute Myeloid Leukemia: A Case Study and Literature Review.
Oncology and therapyNovel agents for myelodysplastic syndromes.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy PractitionersSecond- or third-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukemia in general population: Is there a real benefit?
Cancer medicineMyeloid malignancies with translocation t(4;12)(q11-13;p13): molecular landscape, clonal hierarchy and clinical outcomes.
Journal of cellular and molecular medicineMultiple cranial nerve palsies revealing blast crisis in patient with chronic myeloid leukemia in the accelerated phase under nilotinib during severe infection with SARS-COV-19 virus: Case report and review of literature.
Radiology case reportsEpigenetic focus on angioimmunoblastic T-cell lymphoma: pathogenesis and treatment.
Current opinion in oncology[Overview of the general management of acute leukemia for adults].
Revue medicale de LiegeAn overview of genetic predisposition to familial hematological malignancies.
Bulletin du cancerFlexible Modeling of Net Survival and Cure by AML Subtype and Age: A French Population-Based Study from FRANCIM.
Journal of clinical medicineHeamatological malignancies in giant cell arteritis: a French population-based study.
Rheumatology (Oxford, England)[Behçet's-like syndrome and other dysimmunitary manifestations related to myelodysplastic syndromes with trisomy 8].
La Revue de medecine interne[Erythrophagocytosis by blast cells and de novo T cell LAL without cytogenetic abnormalities in a Moroccan patient].
The Pan African medical journalClonal haematopoiesis is increased in early onset in systemic sclerosis.
Rheumatology (Oxford, England)Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials.
Cancer medicine[Diagnostic workup in front of an hypereosinophilia in 2020].
Annales de biologie cliniqueInfant cancers in France: Incidence and survival (2000-2014).
Cancer epidemiologyCorrelation of histological marrow characteristics and intravoxel incoherent motion-derived parameters in benign and malignant hematological disorders.
European journal of radiology[Haploidentical hematopoietic stem cell transplant: How to choose the best donor? Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Bulletin du cancer[Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia].
Bulletin du cancer[Clonal haematopoiesis: A concise review].
La Revue de medecine interneUsing healthcare claims data to analyze the prevalence of BCR-ABL-positive chronic myeloid leukemia in France: A nationwide population-based study.
Cancer medicineA novel thiosemicarbazone as a promising effective and selective compound for acute leukemia.
Anti-cancer drugsPREDOMOS study, impact of a social intervention program for socially isolated elderly cancer patients: update to the study protocol for a randomized controlled trial.
TrialsPoor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia.
HaematologicaMICONIDINE acetate, a new selective and cytotoxic compound with synergic potential, induces cell cycle arrest and apoptosis in leukemia cells.
Investigational new drugsStable Isotope Labeling Highlights Enhanced Fatty Acid and Lipid Metabolism in Human Acute Myeloid Leukemia.
International journal of molecular sciencesInflammatory disorders associated with trisomy 8-myelodysplastic syndromes: French retrospective case-control study.
European journal of haematologyEpidemiology of malignant hemopathies recorded in hospitals in Cameroon.
Medecine et sante tropicalesTo chelate or not to chelate in MDS: That is the question!
Blood reviewsGlobal surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.
Lancet (London, England)In Vitro Culture with Interleukin-15 Leads to Expression of Activating Receptors and Recovery of Natural Killer Cell Function in Acute Myeloid Leukemia Patients.
Frontiers in immunologyThe IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development.
Proceedings of the National Academy of Sciences of the United States of AmericaBiological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.
Clinical cancer research : an official journal of the American Association for Cancer ResearchCytogenetics in the management of acute myeloid leukemia: an update by the Groupe francophone de cytogénétique hématologique (GFCH).
Annales de biologie cliniqueCancer incidence in France over the 1980-2012 period: Hematological malignancies.
Revue d'epidemiologie et de sante publiqueThe level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.
BloodA minireview on NHE1 inhibitors. A rediscovered hope in oncohematology.
Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia[Myelodysplastic syndromes: pathophysiology, clinical and biological features].
Annales de biologie cliniqueSurvival variations by country and age for lymphoid and myeloid malignancies in Europe 2000-2007: Results of EUROCARE-5 population-based study.
European journal of cancer (Oxford, England : 1990)Molecular characterization and follow-up of five CML patients with new BCR-ABL1 fusion transcripts.
Genes, chromosomes & cancer3q26/EVI1 rearrangements in myeloid hemopathies: a cytogenetic review.
Future oncology (London, England)Associações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Hemopatia mieloide.
É de uma associação que acompanha esta doença? Fale com a gente →
Doença com base genética
Um médico geneticista pode ajudar no diagnóstico de Hemopatia mieloide e no aconselhamento genético da família.
Doenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Perguntas frequentes
O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu
Trata-se de uma categoria nosológica que reúne condições que afetam as células mieloides da medula óssea e do sangue. No catálogo internacional Orphanet, está classificada sob o código ORPHA:171895.
Referências
Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete
4 fontes citadas no texto · 10 publicações do grafo RarasNet (PubMed) · 5 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Citar este verbete
Raras. (2026). Hemopatia mieloide. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/hemopatia-mieloide
Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
Hemopatia mieloide
📋 Origem dos dados
Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.
- Doença rara (ontologia)
- fonte: Orphanet
- Identificador unificado
- fonte: MONDO
- NIH/GARD
- fonte: GARD (NIH)
- Dado público estruturado
- fonte: Wikidata
- Moléculas estudadas na doença
- fonte: OpenTargets